AMD

Neovascular macular degeneration is multifactorial, which requires future agents to target multiple pathways.

"The De Novo authorization established Valeda as the first device for treatment of dry AMD patients with vision loss and creates a threshold for this novel class of photobiomodulation (PBM) devices..."

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD).

Peking University researchers have developed a deep learning-based, noninvasive choroidal angiography method that enables detailed 3D visualization of choroidal vessels from OCT scans. This technique could improve diagnostics for retinal diseases like macular degeneration, offering a safer alternative to traditional methods.

The company noted that its GalOmic pipeline includes ETX-407 for the treatment of dry age-related macular degeneration (AMD).

A $6.4 million grant over 5 years from the National Institutes of Health’s National Eye Institute was awarded conduct drug development work and investigational new drug (IND)-enabling toxicology studies.

A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that promotes blood vessel growth. Combining anti-VEGF with an experimental drug targeting HIF-1 could enhance vision outcomes and prevent vision loss.

Scientists have identified several small molecule drugs that selectively expand RPEs to regenerate a functional RPE layer.

The study is now expected to be fully enrolled with all 300 patients randomized by the end of 2024.

PMC-403 is a novel TIE2-activating antibody with a mechanism that stabilizes pathological, leaky blood vessels.

Non-invasive, painless laser can reduce risk of vision loss

A new study described the underlying defect responsible for development of AMD and related macular dystrophies (MDs).

Socioeconomic factors have long been a looming issue in various health outcomes. A team of researchers from Shanghai Jiao Tong University School of Medicine and Fudan University set out to review the impact of socioeconomic status inequality on the incidence of AMD.

The data were presented at the Keystone Symposium Targeting Dry Age-related Macular Degeneration: Pathophysiology and Emerging Therapies.

The PPQ campaign consisted of the production of 3 successful consecutive commercial-scale drug substance batches required for the validation of Opthea’s manufacturing process.

4D Molecular Therapeutics has announced data based on the longest interim follow-up from Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design.

Gene therapy offers a promising alternative by potentially providing long-lasting effects from a single treatment.

Research by investigators at Trinity College in Dublin shows how the gene therapy conferred significant benefit in animal models, and in human cells derived from people with glaucoma.

This certification covers AI based regulatory requirements for the company's platform for AI imaging and diagnostic tools.

Data from this trial will be reported ahead of AAO 2024 in Chicago, Illinois.

InMed Pharmaceuticals has been issued 3 US patents, one of which is for an ocular drug delivery formulation for potential use in AMD.

The next step for the research likely will focus on determining whether blocking GSK3 can reverse existing AMD damage, potentially leading to new treatment options.

According to the company, the pre-clinical safety and efficacy studies of its product have yielded positive results in 3 internationally recognized labs in India, Singapore and the United States.

According to the company, the FDA approval strengthens its biosimilar position in the US market.

The CPT code is the first to report photobiomodulation therapy in retinal disease.

The SOL-R clinical trial of is deemed appropriate for use as Ocular Therapeutix’s second adequate and well controlled study of axitinib intravitreal implant.

According to the company, the wearable smart glasses with both vision enhancement and assistance will be introduced at the American Retina Forum National Meeting

LUBT010 is a ranibizumab biosimilar to Lucentis that achieved its primary endpoint in this study.